Also, it remains uncertain whether the prognosis of secondary AML with a CEBPA double mutation after APL is equivalent to that of newly diagnosed AML with a CEBPA double mutation, thus additional clinical cases are needed. The gene discussed is CEBPA; the disease is acute promyelocytic leukemia.